Market capitalization | $181.27m |
Enterprise Value | $236.32m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.18 |
P/S ratio (TTM) P/S ratio | 3.97 |
P/B ratio (TTM) P/B ratio | 0.79 |
Revenue growth (TTM) Revenue growth | -68.73% |
Revenue (TTM) Revenue | $45.62m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
5 Analysts have issued a 2seventy bio forecast:
5 Analysts have issued a 2seventy bio forecast:
Sep '24 |
+/-
%
|
||
Revenue | 46 46 |
69%
69%
|
|
Gross Profit | 20 20 |
81%
81%
|
|
EBITDA | -134 -134 |
23%
23%
|
EBIT (Operating Income) EBIT | -142 -142 |
23%
23%
|
Net Profit | -95 -95 |
49%
49%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Chip Baird |
Employees | 274 |
Founded | 2021 |
Website | www.2seventybio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.